20 Future Finnish HealthTech and MedTech Leaders

Nelson Advisors
Mar 30
14 min read

Updated: 7 days ago

20 Future Finnish HealthTech and MedTech Leaders

The Finnish healthcare technology sector has undergone a profound transformation, evolving from a niche engineering discipline into the nation's most significant high-tech export industry. By early 2026, the sector has established itself as a global paradigm for how a small, digitally advanced nation can leverage longitudinal data and institutional trust to solve systemic global healthcare challenges.

This transition is anchored in a unique structural advantage: a century of digitised health data and a legislative framework that permits the ethical, secondary use of this data for research and development.As global healthcare systems grapple with acute staffing shortages, aging populations, and rising costs, the Finnish ecosystem offers a blueprint for data-driven, human-centric innovation.

The Macroeconomic Landscape and Structural Foundations

The robustness of the Finnish HealthTech ecosystem is evidenced by its significant contribution to national exports, reaching an estimated €856 Million to the United States alone in 2024. This growth is not accidental but is the result of decades of strategic public-private collaboration. Central to this infrastructure is the "Kanta" national platform, which has provided secure, seamless data access for both professionals and citizens for over a decade.

Furthermore, the Act on the Secondary Use of Health Data has positioned Finland as a premier global destination for pharmaceutical R&D and clinical trials, allowing for the rapid identification of patient cohorts and real-world evidence (RWE) generation.

The investment climate in 2025 reflected this maturity. Finnish deep tech companies, a category that heavily overlaps with MedTech and BioTech, set a record by raising nearly €1.6 Billion, a staggering 170% increase over 2024. While mega-rounds for companies like Oura and IQM dominated the capital inflow, the ecosystem also saw a revitalisation of seed and early-stage funding, supported by a diverse array of domestic and international venture capital firms.

Investment and Funding Dynamics in 2025–2026

The following table outlines the leading venture capital entities that have been instrumental in fueling the current wave of Finnish health innovation. Their focus ranges from pre-seed software to capital-intensive deep tech and hardware.

Investor Name	Focus and Investment Strategy	Health-Related Portfolio Strength
Butterfly Ventures	Pre-seed and seed hardware and deep tech specialists.	17 Investments
Lifeline Ventures	Early-stage growth across health, tech, and consumer.	16 Investments
Business Finland	Public R&D funding and internationalization grants.	15 Strategic Programs
Finnvera	State-owned provider of loans and guarantees for scaling.	15 Growth Packages
Voima Ventures	Science-based startups and deep tech commercialization.	13 Investments
Tesi (Finnish Industry Investment)	Late-stage and industrial scaling with social impact.	13 Investments
Icebreaker.vc	Software-focused pre-seed and team building.	12 Investments
Innovestor	Life sciences, healthtech, and sustainable innovation.	11 Investments

The data indicates a robust pipeline where early-stage firms (supported by Icebreaker and Butterfly) are increasingly finding follow-on capital from Tesi and international investors. However, analysts note that the link between early and later-stage funding (Series A and B) remains an area for continued development to prevent "innovation leakage" to other European hubs.

Regional Clusters: The Engines of Innovation

Finland’s health innovation is concentrated in three primary clusters, Helsinki, Oulu, and Turku, each possessing a distinct technological and clinical identity.

The Helsinki Metropolitan Cluster: Biopharma and Digital Integration

Helsinki acts as the administrative and financial heart of the ecosystem. It is home to the Helsinki University Hospital (HUS), which coordinates the CleverHealth Network. This ecosystem leverages HUS's high-quality clinical data to co-develop solutions with global partners like AstraZeneca, GE Healthcare, and Microsoft.

The focus here is on the deep integration of AI into clinical pathways and the development of world-class biopharmaceuticals.

The Oulu Cluster: Wireless Connectivity and MedTech Hardware

Oulu is globally renowned for its history in telecommunications, a legacy that has pivoted toward "Wireless Health." The OuluHealth ecosystem integrates 5G and IoT expertise into medical devices. Oulu is unique in its "TestLab" environment, where 5G technology is piloted in real-time hospital operations to support remote surgery, real-time patient monitoring, and autonomous hospital logistics.

The Turku Cluster: Pharmaceutical Development and Manufacturing

Turku remains the stronghold of Finland’s pharmaceutical industry. It serves as a global hub for Bayer’s contraceptive R&D and manufacturing, and it is the home of Orion Corporation, the nation’s largest domestic pharmaceutical company.The region benefits from the "Veturi" program, a challenge competition designed to expand the pharmaceutical innovation ecosystem through large-scale R&D investments.

The 20 Future Leaders of Finnish HealthTech and MedTech

The companies identified below represent the most promising ventures poised for global leadership in the 2025–2026 period. These leaders have been selected based on their technological sophistication, clinical validation, funding success, and strategic alignment with global healthcare needs.

1. TILT Biotherapeutics: The Vanguard of Oncolytic Immunotherapy

TILT Biotherapeutics, founded by Professor Akseli Hemminki in 2013, has emerged as a premier developer of oncolytic viruses for the treatment of solid tumors. The company's proprietary technology involves engineering adenoviruses to deliver immune-stimulating cytokines directly into the tumuor microenvironment. This approach is designed to overcome the "cold" immunosuppressive nature of many solid tumours, making them susceptible to the patient's own T-cells.

In early 2025, TILT closed a $25 Million Series B funding round to accelerate its clinical trials. Data presented at the ESMO Congress 2025 demonstrated significant survival benefits and clinical correlations in ovarian cancer patients treated intravenously. The company is actively pursuing partnerships with global biopharma firms and is a regular fixture at major industry summits, including BIO-Europe and the ASCO Annual Meeting.

2. Gosta Labs: Redefining Clinical Workflows with AI

Gosta Labs addresses one of the most critical issues in modern healthcare: clinician burnout. Founded by former Kaiku Health entrepreneurs, Gosta Labs has developed an "AI Operating System" for healthcare professionals. The platform uses medical-grade AI to automate clinical documentation, patient data structuring, and the surfacing of real-time clinical insights.

By February 2026, Gosta Labs became the first AI OS to be registered as a medical device in the European EUDAMED database. The company has expanded its operations to France and secured €7.5 Million in seed funding led by Voima Ventures. Its ability to reduce administrative pressure is being demonstrated in partnerships with major Finnish private providers like Aava and public wellbeing services in Satakunta and Kirkkonummi.

3. Solid IO: Precision Oncology through Tumour-on-Chip Technology

Solid IO is a biotech innovator specialising in patient-specific tumour-immune response modeling. Their "tumour-on-chip" technology replicates an individual patient's unique tumor microenvironment using bioengineering and AI. This allows oncologists to test the efficacy of various immuno-oncology treatments before they are administered, effectively eliminating the trial-and-error approach common in cancer therapy.

Founded in 2025, the company has quickly gained international visibility, particularly at the HLTH USA 2025 conference.With €800,000 in early-stage funding, Solid IO is expanding its collaborations with pharmaceutical partners to integrate its platform into drug development pipelines, aiming to improve the success rate of new cancer therapies.

4. Nadmed: Standardising NAD Diagnostics

Nadmed provides advanced diagnostic solutions for measuring nicotinamide adenine dinucleotide (NAD) levels—a key biomarker for energy metabolism and cellular health. Low NAD levels are increasingly linked to aging, metabolic disorders, and neurodegenerative diseases. Nadmed’s technology allows for accurate measurement using fresh blood samples, a significant advancement over previous, less reliable methods.

The company, led by CEO Jari Närhi, has raised $4 Million and established manufacturing operations in California to serve the US market. Nadmed was a standout participant in the 2025 Business Finland Amplify program, which facilitates direct engagement with the Mayo Clinic.

5. Medicubex: The Autonomous eHealth Station

Medicubex has addressed the primary care access crisis with its eHealth Station™, a self-service kiosk that enables patients to perform a comprehensive health check in five minutes. The station measures vital signs including blood pressure, ECG, and blood oxygen, and uses AI to provide immediate risk assessments for cardiovascular and metabolic conditions.

In 2025, Medicubex won a €4 million tender to deploy these stations across 15 Finnish wellbeing services counties.Internationally, the company has partnered with the Frankfurt University Hospital and was selected for the German Medical Forge accelerator. With over €3 Million in total funding, Medicubex is scaling rapidly across Europe and the UK.

6. CurifyLabs: Digitalising Personalised Medicine

CurifyLabs is transforming the compounding pharmacy sector with its automated "PharmaPrinter Aurum" system. By using 3D-printing inspired technology, CurifyLabs allows pharmacies to manufacture personalised medicines tailored to a patient’s specific dosage, flavour and release profile.

The company’s solution ensures digital traceability and compliance, which are major hurdles in traditional manual compounding. In 2025, CurifyLabs conducted a global "World Tour," showcasing its technology at major forums like the APhA in Nashville and the EAHP Congress in Copenhagen. The company is strategically positioned to lead the shift toward mass customisation in pharmaceuticals.

7. Oura Health: The Medical-Grade Wearable Pioneer

Oura Health has transitioned from a popular sleep tracker to a foundational tool for population health and clinical research. In 2025, the company raised $900 Million, reaching a valuation of $11 Billion. This funding is being used to enhance Oura’s AI capabilities, moving toward predictive health analytics that can detect the early onset of illness based on biometric deviations.

Oura’s success demonstrates the Finnish ability to combine high-end sensor engineering with sophisticated data science.By 2026, the Oura Ring is increasingly integrated into employer-sponsored wellness programs and clinical trials as a validated tool for continuous biometric monitoring.

8. Otos Health: Accelerating Hearing Diagnostics

Otos Health addresses the "invisible" epidemic of hearing loss. Their automated hearing diagnostics system enables non-clinical staff to perform gold-standard hearing tests in parallel, reducing the time required by 50%. This "triage-at-the-source" model allows primary care clinics to identify hearing issues earlier and refer patients more effectively.

Led by CEO Wycliffe Raduma and CTO Ville Sivonen, Otos Health is a key beneficiary of the Business Finland Health 360 program. The company was selected for the Finland Pavilion at HLTH USA 2025, seeking to enter the US market where hearing aid deregulation and the aging population are driving demand for accessible diagnostics.

9. Buddy Healthcare: Care Coordination and Patient Engagement

Buddy Healthcare’s platform automates patient communication and streamlines perioperative care pathways. By digitising forms, pre-operative assessments, and patient-reported outcomes (PROs), the platform reduces the administrative burden on hospital staff while improving patient compliance and recovery outcomes.

Hospitals using Buddy Healthcare report a 98% reduction in phone calls and a 30% reduction in surgical cancellations.The company is actively expanding in the US and Europe, focusing on high-volume surgical specialties like orthopaedics and cardiology.

10. Monidor: Intelligent Infusion Monitoring

Monidor, based in Oulu, has developed a remote monitoring solution for intravenous (IV) infusion therapy. Their technology allows nurses to monitor infusion rates and fluid levels from a central station, ensuring patient safety and improving nursing workflow efficiency.

The system is designed to integrate seamlessly into existing hospital IT infrastructures and has seen strong adoption in Finnish and Nordic hospitals. Monidor’s growth is fuelled by the critical need to optimise hospital resources amid global nursing shortages.

11. Cerenion: AI for Critical Care Brain Monitoring

Cerenion provides an AI-powered bedside EEG monitoring solution specifically designed for intensive care units (ICUs).Their "C-Trend" technology translates complex EEG signals into a simple "brain state" index, allowing non-specialists to monitor the neurological status of critically ill patients.

Founded in 2017 in Oulu, Cerenion bridges the gap between academic research in clinical neurophysiology and the practical needs of emergency medicine. The company is currently scaling its international presence, targeting ICUs where early detection of neurological complications can significantly improve patient survival rates.

12. Medanets: Empowering the Mobile Clinician

Medanets provides mobile solutions that allow healthcare professionals to document vital signs and access patient data directly at the bedside. By integrating with existing electronic health records, Medanets eliminates the need for manual transcription, reducing errors and saving clinicians significant amounts of time.

With a history dating back to 2004, Medanets is a mature leader in the Finnish digital health space, serving public healthcare organizations across Europe. The company continues to innovate by adding AI-driven decision-support features to its mobile platform.

13. Ounas Health: Care Connectivity and Workflow Automation

Ounas Health has developed a modular, AI-driven care connectivity platform designed to automate clinical workflows.The platform acts as a digital orchestrator, ensuring that clinical data from various sensors and systems is directed to the appropriate clinical team members in real-time.

This "connectivity-as-a-service" model is particularly relevant for modern "smart hospitals" that utilize a multitude of disparate digital tools. Ounas Health is part of the high-tech MedTech cluster in Oulu, leveraging the region’s heritage in telecommunications and systems integration.

14. Nucu: Science-Based Sleep for Infants

Giving sleep a voice to support growing minds from childhood to young adulthood.At Nucu, we believe that sleep is the most powerful tool for a developing brain. It is the foundation for a child’s growth, focus, and happiness—yet millions of kids and teens struggle with bedtime routines, restless nights, and tired mornings.We are redefining sleep health for children and teenagers aged 4–18 with safe, non-wearable technology that helps them sleep better, grow stronger, and thrive. By giving sleep a voice, we provide families with the insights needed to support growing minds during their most formative years.

We offer advanced contact-free sleep monitoring for kids and teens aged 4-18 years, which easily integrates with any bed. In an instant, your kids’ bed becomes a smart bed with Nucu. The Nucu hub also monitors the sleep environment, including temperature, humidity, ambient light, and noise levels. It provides parents and children with AI-powered insights through the Nucu companion mobile app to support better sleep, health, and development.

15. Koite Health: Photodynamic Oral Care

Koite Health has gained international attention for its Lumoral device, which uses photodynamic therapy to target the bacteria responsible for periodontitis and dental decay. This non-invasive, non-antibiotic treatment is particularly important in the context of the global rise in antimicrobial resistance.

Koite Health participated in the Finland Pavilion at HLTH USA 2025, where it highlighted the systemic link between oral health and chronic conditions like cardiovascular disease and diabetes. The company is scaling its consumer and professional distribution networks across Europe and North America.

16. Sartar Therapeutics: Repurposing Drugs for Rare Cancers

Sartar Therapeutics is a biotech firm focusing on soft tissue sarcomas and other difficult-to-treat cancers. The company uses a precision-led approach to repurpose existing drugs, optimising their delivery to specific tumour types where there is a high unmet clinical need.

In late 2025, Sartar secured funding alongside Medicubex to advance its clinical pipeline. By utilising the Finnish biobank system and the Fingenious ecosystem, Sartar can rapidly validate its therapeutic targets and move toward late-stage clinical trials.

17. Polku Therapeutics: Targeting Neurodegeneration

Founded in 2023, Polku Therapeutics is a discovery-stage biotech company developing small molecule drugs for neurodegenerative diseases like Parkinson’s and Alzheimer’s. The founding team includes leading experts in pharmacology and neurology from the University of Helsinki.

Polku has raised $2.3 Million to date. Their research focuses on modulating protein aggregation and neuroinflammation, two key drivers of neurodegenerative decline. As the global population ages, Polku’s science-heavy approach makes it a prime candidate for future acquisition or partnership with major pharmaceutical firms.

18. EpiHeart: Advanced Cardiac Micrograft Therapy

EpiHeart is a medical device innovator focused on enabling "Cardiac Micrograft Therapy" during surgical interventions.This therapy involves applying a micrograft of the patient's own tissue to areas of the heart damaged by lack of oxygen (ischemia), promoting healing and preventing heart failure.

EpiHeart is currently moving through the clinical validation and commercialization phases for its micrograft processing kits. The company represents the high-end surgical innovation occurring within the Helsinki health ecosystem.

19. Maculaser: Fighting Blindness with Controlled Heat

Maculaser has developed a novel medical device for treating retinal diseases, specifically focusing on age-related macular degeneration (AMD). Their technology uses precisely controlled laser-induced heat to stimulate the retinal pigment epithelium, aiming to restore its function and halt the progression of blindness.

Maculaser’s approach is a non-invasive alternative to the intravitreal injections that are currently the standard of care for wet AMD. The company is currently engaged in clinical trials to validate the long-term safety and efficacy of its treatment.

20. Moncyte Health: Precision Lipid Diagnostics

Moncyte Health provides a "cellular lipid-fingerprint" diagnostic for cardiovascular disease risk. Unlike traditional cholesterol tests, Moncyte’s technology analyses how cells actually process lipids, providing a personalised risk profile that can guide more effective treatment plans.

This "lipidomics" approach allows for the elimination of treatment trial-and-error, ensuring that patients receive the most appropriate lipid-lowering therapies early on. Moncyte was featured in the Finland Pavilion at HLTH USA 2025, positioning itself as a leader in the next generation of preventative cardiovascular diagnostics.

Strategic Internationalisation: The North American Frontier

A defining characteristic of the 2025–2026 period is the Finnish health sector’s aggressive pursuit of the North American market. The United States remains the largest global market for health technology, and Finnish companies are increasingly viewed as stable, innovative partners amid ongoing global geopolitical uncertainty.

The Mayo Clinic Partnership and the AMPlify Program

Business Finland’s AMPlify program represents a significant strategic bridge between Finland and the Mayo Clinic, which has been consistently voted the world’s best hospital. The program provides Finnish companies with direct access to Mayo Clinic experts, clinical decision-makers, and investors.

AMPlify Program Phase	Key Activities and Outcomes
Curated Workshops	Expert-led sessions on U.S. regulatory (FDA) and reimbursement pathways.
Mentorship	One-on-one sessions with Mayo Clinic key opinion leaders (KOLs).
Investor Insights	Pitching opportunities to U.S.-based healthcare venture capital firms.
On-Site Visit	A November 2026 delegation to Mayo Clinic, Rochester, Minnesota.
Market Entry	Development of scalable collaboration and commercialization pathways.

Of the 25 companies that applied for the 2025 AMPlify cohort, 11 were selected, including leaders like Nadmed, Otos Health, and MultivisionDx. This program has already resulted in seven term sheet offers, demonstrating the high level of American interest in Finnish innovation.

The Global Outreach Missions

In March 2026, a high-level Finnish government delegation is scheduled to visit the major healthcare hubs of New York and Boston. This visit targets influential institutions such as Memorial Sloan Kettering, Pfizer, and the Broad Institute.The goal is to solidify Finland’s reputation as a world-class health innovation partner and to facilitate high-level connections for companies in the oncology, imaging, and health data sectors.

Analysing Sector Trends: The Future of Global Health

The leaders identified in this report are navigating a landscape defined by several transformative trends that will dictate the next decade of healthcare.

1. AI as the Stabilizing Force for the Workforce

The global healthcare staffing crisis has reached a breaking point, with burnout affecting nearly 48% of employees worldwide. Finnish companies are responding by positioning AI not just as a tool for clinical insight, but as a "daily workhorse" that stabilizes the workforce. By automating documentation (Gosta Labs) and routine checks (Medicubex), these technologies provide clinicians with the "gift of time," allowing them to focus on high-value patient care.

2. The Resurgence of MedTech M&A

Following a surge in deal value to $97.6 billion in 2025, the MedTech M&A market is entering 2026 with strong momentum. Acquirers are increasingly seeking targets that offer "connected-care" ecosystems and AI-driven analytics.Finnish companies, with their strong focus on data integration and interoperability, are highly attractive targets for global strategics looking to modernise their portfolios.

3. Sustainability as a Core Metric

In 2025, 87% of transactions within the Business Finland Health 360 program met stringent responsibility and sustainability objectives. This reflects a broader trend where healthcare companies are increasingly rewarded for demonstrating their commitment to environmental, social, and governance (ESG) goals. This is particularly evident in sectors like remote monitoring and digital health, which naturally reduce the carbon footprint of healthcare delivery.

Conclusion: Finland's Role in the Global Healthcare Renaissance

The Finnish HealthTech and MedTech ecosystem is currently at an inflection point. The combination of a robust domestic testbed environment, unparalleled health data resources and a strategic focus on internationalization has created a unique launchpad for high-impact innovation.

The 20 leaders identified in this report, from the biopharmaceutical pioneers like TILT Biotherapeutics to the digital health innovators like Gosta Labs, are not only building successful businesses but are also providing scalable solutions to some of humanity's most pressing health challenges.

As the industry moves through 2026, the success of these companies will be measured by their ability to navigate the complexities of the US and European markets while maintaining the "sisu", the uniquely Finnish characteristic of resilience and determination, that has brought them to the global stage. The future of healthcare is increasingly human-centric, digital, and data-driven, and in this future, Finland is poised to lead.

Nelson Advisors > European MedTech and HealthTech Investment Banking

Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital

Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb

Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk

#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech